Can lacosamide be taken with maois?

Can lacosamide interact with MAOIs?

Lacosamide and MAOIs affect the central nervous system in different ways. Lacosamide stabilizes neuronal membranes by selectively enhancing slow inactivation of sodium channels. MAOIs block the breakdown of neurotransmitters such as serotonin, norepinephrine, and dopamine. No published pharmacokinetic studies show direct metabolic interference between the two, yet the combination carries a theoretical risk of additive CNS depression or serotonin-related effects.

When should patients avoid combining them?

Most prescribing information for lacosamide lists MAOIs among the drugs that require caution or monitoring. Because lacosamide can produce dizziness, somnolence, or cardiac conduction changes, clinicians generally recommend spacing administration or avoiding concurrent use unless the benefit clearly outweighs the risk. If an MAOI is essential, physicians often start lacosamide at a low dose and titrate slowly while watching for excessive sedation or changes in heart rhythm.

Are there documented case reports or clinical data?

Public adverse-event databases contain few specific reports of lacosamide-MAOI interactions. Available post-marketing surveillance has not identified a consistent pattern of serotonin syndrome or hypertensive crisis. However, absence of reports does not prove safety; individual patient factors such as age, hepatic function, or concurrent medications can alter risk.

What alternatives exist if an MAOI is required?

If an MAOI must be continued, neurologists may choose antiepileptics with established safety records alongside MAOIs, such as levetiracetam or lamotrigine, provided seizure control remains adequate. Dose adjustments and close clinical follow-up are standard when any new anticonvulsant is added.

When does lacosamide’s patent protection end?

Lacosamide’s U.S. composition-of-matter patent expired in 2022; several generic versions are now marketed. Formulation and method-of-use patents extend protection for certain indications into the late 2020s, according to DrugPatentWatch.com.